Gene and protein expression and cellular localisation of cytochrome P450 enzymes of the 1A, 2A, 2C, 2D and 2E subfamilies in equine intestine and liver

Acta Veterinaria Scandinavica

Eva Tydén¹  Hans Tjälve¹  Pia Larsson¹ 

[1] Department of Biomedical Sciences and Veterinary Public Health, Division of Pathology, Pharmacology and Toxicology, Swedish University of Agricultural Sciences, Uppsala, S-750 07, Sweden

关键词: Intestine;    Liver;    Cellular localisation;    Protein expression;    Gene expression;    Horse;    CYP;   

Others  :  1082541
DOI  :  10.1186/s13028-014-0069-8

 received in 2014-05-28, accepted in 2014-10-03,  发布年份 2014

【 摘 要 】

Background

Among the cytochrome P450 enzymes (CYP), families 1–3 constitute almost half of total CYPs in mammals and play a central role in metabolism of a wide range of pharmaceuticals. This study investigated gene and protein expression and cellular localisation of CYP1A, CYP2A, CYP2C, CYP2D and CYP2E in equine intestine and liver. Real-time polymerase chain reaction (RT-PCR) was used to analyse gene expression, western blot to examine protein expression and immunohistochemical analyses to investigate cellular localisation.

Results

CYP1A and CYP2C were the CYPs with the highest gene expression in the intestine and also showed considerable gene expression in the liver. CYP2E and CYP2A showed the highest gene expression in the liver. CYP2E showed moderate intestinal gene expression, whereas that of CYP2A was very low or undetectable. For CYP2D, rather low gene expression levels were found in both intestine and the liver. In the intestine, CYP gene expression levels, except for CYP2E, exhibited patterns resembling those of the proteins, indicating that intestinal protein expression of these CYPs is regulated at the transcriptional level. For CYP2E, the results showed that the intestinal gene expression did not correlate to any visible protein expression, indicating that intestinal protein expression of this CYP is regulated at the post-transcriptional level. Immunostaining of intestine tissue samples showed preferential CYP staining in enterocytes at the tips of intestinal villi in the small intestine. In the liver, all CYPs showed preferential localisation in the centrilobular hepatocytes.

Conclusions

Overall, different gene expression profiles were displayed by the CYPs examined in equine intestine and liver. The CYPs present in the intestine may act in concert with those in the liver to affect the oral bioavailability and therapeutic efficiency of substrate drugs. In addition, they may play a role in first-pass metabolism of feed constituents and of herbal supplements used in equine practice.

【 授权许可】

   
2014 Tydén et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Nebert DW, Russell DW: Clinical importance of the cytochromes P450. Lancet 2002, 360:1155-1162.
• [2]Ding X, Kaminsky LS: Human extrahepatic cytochromes P450: functiona in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003, 43:149-173.
• [3]Tydén E, Löfgren M, Hakhverdyan M, Tjälve H, Larsson P: The genes of all seven CYP3A isoenzymes identified in the equine genome are expressed in the airways of horses. J Vet Pharmacol Ther 2013, 36:370-375.
• [4]Knych HK, Stanley SD: Complementary DNA cloning, functional expression and characterization of a novel cytochrome P450, CYP2D50, from equine liver. Biochem Pharmacol 2008, 76:904-911.
• [5]Knych HK, DeStefano SC, Buckpitt AB, Stanley SD: Equine cytochrome P450 2C92: cDNA cloning, expression and initial characterization. Arch Biochem Biophys 2009, 485:49-55.
• [6]Knych HK, McKemie S, Stanley D: Molecular cloning, expression, and initial characterization of members of the CYP3A family in horses. Drug Metab Disp 2010, 38:1820-1827.
• [7]Girma K: Försäljningsutveckling av djurläkemedel 2011. [Sales development of veterinary drugs 2011].Board of Agriculture 2012, 7–10.
• [8]Williams CA, Lamprecht ED: Some commonly fed herbs and other functional foods in equine nutrition: a review. Vet J 2008, 178:21-31.
• [9]Nebbia C, Dacasto M, Rossetto Giaccherino A, Giuliano A, Carletti M: Comparative expression of liver cytochrome P450-dependent monooxygenases in the horse and in other agricultural and laboratory species. Vet J 2003, 165:53-64.
• [10]Fink-Gremmels J: Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. Eur J Clin Pharm 2008, 585:502-509.
• [11]Tydén E, Olsen L, Tallkvist J, Larsson P, Tjälve H: CYP3A in horse intestines. Toxicol Appl Pharm 2004, 201:112-119.
• [12]Tydén E, Löfgren M, Pegolo S, Capolongo F, Tjälve H, Larsson P: Differential gene expression of CYP3A isoforms in equine liver and intestines. J Vet Pharmacol Ther 2012, 35:588-595.
• [13]Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC: The human intestinal cytochrome P450 "pie". Drug Metab Dispos 2006, 34:880-886.
• [14]Mitschke D, Reichel A, Fricker G, Moenning U: Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab Dispos 2008, 36:1039-1045.
• [15]Tydén E, Olsen L, Tallkvist J, Tjälve H, Larsson P: Cytochrome P450 3A, NADPH cytochrome P450 reductase and cytochrome b5 in the upper airways in horse. Res Vet Sci 2008, 85:80-85.
• [16]Tydén E, Tallkvist J, Tjälve H, Larsson P: P-glycoprotein in intestines, liver, kidney and lymphocytes in horse. J Vet Pharmacol Ther 2009, 32:167-176.
• [17]Yasukochi Y, Satta S: Evolution of the CYP2D gene cluster in humans and four non-human primates. Genes Genet Syst 2011, 86:109-116.
• [18]Nelson DR: The cytochrome P450 homepage. Hum Genom 2009, 4:59-65.
• [19]Rozen S, Skaletsky HJ: Primer3 on the WWW for general users and for biologist programmers. [http://primer3.ut.ee/] webciteIn Bioinformatics Methods and Protocols. Methods in Molecular Biology Humana Press Totowa 2000 Edited by Krawetz S, Misener S. 2000, 365-386. software version 4.0. http://primer3.ut.ee/
• [20]Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
• [21]Zhang Q-Y, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS: Characterization of human small intestinal cytochromes P-450. Drug Metab Disp 1999, 27:804-809.
• [22]Shin HC, Kim HR, Cho HJ, Yi H, Cho SM, Lee DG, El-Aty AM, Kim JS, Sun D, Amidon GL: Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Disp 2009, 30:411-421.
• [23]Buchthal J, Grund KE, Buchman A, Schrenk D, Beaume P, Bock KW: Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronsyltansferase in biopsies of human duodenal mucosa. Eur J Clin Pharmacol 1995, 47:431-435.
• [24]Fonne-Pfister R, Meyer UA: Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 1988, 37:3829-3835.
• [25]Ingelman-Sundberg M: Genetic polymophism of cytochrome P450 D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diveristy. Pharmacogenomics 2005, 5:6-13.
• [26]Zanger UM, Schwab M: Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic varation. Pharmacol Therapeut 2013, 138:103-141.
• [27]Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I: Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genom 2007, 17:731-742.
• [28]Mealey KL, Jabbes M, Spencer E, Akey JM: Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. Xenobiotica 2008, 38:1305-1312.
• [29]Gonzales F, Lin S, Yano M: Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenet 1993, 3:51-57.
• [30]Dogra S, Whitelaw M, May B: Transcriptional activation of cytochrome p450 genes by different classes of chemical inducers. Clin Exp Pharmacol Physiol 1998, 25:1-9.
• [31]Sumida A, Kinoshita K, Fukada T, Matsuda H, Yamamoto I, Inaba T, Azuma J: Relationship between mRNA levels quantified by reversed transcription – competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Bichem Biophys Res Commun 1999, 262:499-503.
• [32]Rodrigues-Antona C, Donato M, Pureja E, Goméz-Lechón M-J, Castett J: Cytochrome P450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 2001, 393:308-315.
• [33]Enayetallah AE, French RA, Thibodeau MS, Grant DF: Distribution of soluble epoxide hydrolase and cytochrome P450 2C8, 2C9 and 2 J2 in human tissues. J Histochem Cytochem 2006, 52:447-454.
• [34]Uno S, Dragin N, Miller ML, Dalton TP, Gonzalez FJ, Nebert DW: Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tract. Free Radic Biol Med 2008, 44:570-583.
• [35]Thelen K, Dressman JB: Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009, 61:541-558.
• [36]Scarth JP, Teale P, Kuuranne T: Drug metabolism in the horse: a review. Drug Test Anal 2011, 31:19-53.
• [37]Toda T, Ohi K, Kudo T, Yoshida T, Ikarashi N, Ito K, Sugiyama K: Ciprofloxacin suppresses Cyp3a in mouse liver by reducing lithocholic acid-producing intestinal flora. Drug Metab Pharmacokinet 2009, 24:201-208.
• [38]Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ: Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000, 58:361-372.
• [39]Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW: Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica 1998, 28:313-321.
• [40]Skálová L, Szotáková B, Machala M, Neca J, Soucek P, Havlasová J, Wsól V, Krídová L, Kvasnicková E, Lamka J: Effect of ivermectin on activities of cytochrome P450 isoenzymes in mouflon (Ovis musimon) and fallow deer (Dama dama). Chem Biol Interact 2001, 137:155-167.
• [41]Baliharova V, Velik J, Savlik M, Szotakova B, Lamka J, Tahotna L, Skalova L: The effects of fenbendazole, flubendazole and mebendazole on activities of hepatic cytochromes P450 in pig. J Vet Pharmacol Ther 2004, 27:85-90.
• [42]Velík J, Baliharová V, Fink-Gremmels J, Bull S, Lamka J, Skálová L: Benzimidazole drugs and modulation of biotransformation enzymes. Res Vet Sci 2004, 76:95-108.
• [43]Peters LM, Demmel S, Pusch G, Buters JT, Thormann W, Zielinski J, Leeb T, Mevissen M, Schmitz A: Equine cytochrome P450 2B6–genomic identification, expression and functional characterization with ketamine. Toxicol Appl Pharmacol 2013, 266:101-108.
• [44]Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T: Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998, 28:1-13.
• [45]Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, Wang TH: Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy 2011, 31:227-238.
• [46]Ogg MS, Williams JM, Tarbit M, Goldfarb PS, Gray TJ, Gibson GG: A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica 1999, 29:269-279.
• [47]Li X-Q, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa C: Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 2003, 59:429-442.
• [48]Godawska-Matysik A, Kieć-Kononowicz K: Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). Acta Pol Pharm 2006, 63:381-385.
• [49]Zhou S, Koh HL, Gao Y, Gong ZY, Lee EJ: Herbal bioactivation: the good, the bad and the ugly. Life Sci 2004, 74:935-968.
• [50]Doehmer J, Tewes B, Klein KU, Gritzko K, Muschick H, Mengs U: Assessment of drug-drug interaction for silymarin. Toxicol In Vitro 2008, 22:610-617.
• [51]Hodek P, Trefil P, Stiborová M: Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 2002, 139:1-21.